Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Pragmatiston Mar 01, 2021 12:50am
456 Views
Post# 32683348

Insider Buy

Insider Buy
 
 
I think that new investors will look upon this in a favorable light. 
 
Last summer, when there was a bought deal, insiders sold.  This time they bought. This suggests that in contrast to last summer, there might be some positive follow-on news.
 
I appreciate that life is not  as simple as this, but it is still a positive development.
 
If you believe that insiders such as Legault/Wallace will be rewarded with additional shares for an IP consolidation instead of cash or a combination thereof, then this is doubly good, in that they would purchase  additional shares in advance of such a deal.
 
This buy was a private arrangement for insiders, all on the same date and at the same price. And at a price greater than the offering and without the warrants. So it was a coordinated deal outside the Public Offering (PO). Probably with a single SH(s).  Maybe involving the senior broker warrants?
 
So kudos to management for pursuing this when they might have done better with a private placement (PP), where they could have participated at a lower price and with warrants.
 
This is all pure specualation.  But it gives me a warm and fuzzy feeling that I initially didn't have when the bought deal was initially announced. This is good news. Let's see what evolves.
 
<< Previous
Bullboard Posts
Next >>